title: Uric acid: a modulator of prostate cells and activin sensitivity.
abstract: Elevated serum uric acid (SUA) or urate is associated with inflammation and gout. Recent evidence has linked urate to cancers, but little is known about urate effects in prostate cancer. Activins are inflammatory cytokines and negative growth regulators in the prostate. A hallmark of prostate cancer progression is activin insensitivity; however, mechanisms underlying this are unclear. We propose that elevated SUA is associated with prostate cancer counteracting the growth inhibitory effects of activins. The expression of activins A and B, urate transporter GLUT9 and tissue urate levels were examined in human prostate disease. Intracellular and secreted urate and GLUT9 expression were assessed in human prostate cancer cell lines. Furthermore, the effects of urate and probenecid, a known urate transport inhibitor, were determined in combination with activin A. Activin A expression was increased in low-grade prostate cancer, whereas activin B expression was reduced in high-grade prostate cancer. Intracellular urate levels decreased in all prostate pathologies, while GLUT9 expression decreased in benign prostatic hyperplasia, prostatitis and high-grade prostate cancer. Activin responsive LNCaP cells had higher intracellular and lower secreted urate levels than activin-insensitive PC3 cells. GLUT9 expression in prostate cancer cells was progressively lower than in prostate epithelial cells. Elevated extracellular urate was growth promoting in vitro, which was abolished by the gout medication probenecid, and it antagonized the growth inhibitory effects of activins. This study shows for the first time that a change in plasma or intracellular urate levels, possibly involving GLUT9 and a urate efflux transporter, has an impact on prostate cancer cell growth, and that lowering SUA levels in prostate cancer is likely to be therapeutically beneficial.
authors.affiliation: Department of Anatomy, University of Otago, Dunedin, New Zealand.
authors.forename: Febbie
authors.initials: F
authors.lastname: Sangkop
authors.affiliation: Department of Anatomy, University of Otago, Dunedin, New Zealand.
authors.forename: Geeta
authors.initials: G
authors.lastname: Singh
authors.affiliation: Department of Physiology, University of Otago, PO Box 913, Dunedin, 9054, New Zealand.
authors.forename: Ely
authors.initials: E
authors.lastname: Rodrigues
authors.affiliation: Department of Anatomy, University of Otago, Dunedin, New Zealand.
authors.forename: Elspeth
authors.initials: E
authors.lastname: Gold
authors.affiliation: Department of Physiology, University of Otago, PO Box 913, Dunedin, 9054, New Zealand. andrew.bahn@otago.ac.nz.
authors.forename: Andrew
authors.initials: A
authors.lastname: Bahn
mesh_terms: D028341:Activins / Q000378:metabolism*; D045744:Cell Line, Tumor; D051246:Glucose Transport Proteins, Facilitative / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008297:Male; D011339:Probenecid / Q000494:pharmacology; D011467:Prostate / Q000166:cytology* / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology; D012333:RNA, Messenger / Q000378:metabolism; D046888:Tissue Array Analysis; D016212:Transforming Growth Factor beta / Q000378:metabolism; D014527:Uric Acid / Q000378:metabolism*
chemical_list: D051246:Glucose Transport Proteins, Facilitative; D012333:RNA, Messenger; C411811:SLC2A9 protein, human; D016212:Transforming Growth Factor beta; D028341:Activins; D014527:Uric Acid; D011339:Probenecid
keywords: GLUT9; Gout; Hyperuricaemia; Probenecid; SUA; TGFβ